In a post on To the Point, former congressman Henry Waxman and colleagues Bill Corr and Kristi Martin explain how the Bipartisan Budget Act of 2018 ensures that manufacturers of brand-name drugs cannot take advantage of inappropriately low Medicaid rebates. The deal also includes two other provisions that should save Medicare beneficiaries and the federal government money.
